Tonix Pharma Shareholders Approve Reverse Split and Incentive Plan

The latest update is out from Tonix Pharma ( (TNXP) ).

Tonix Pharmaceuticals Holding Corp. held its annual meeting of shareholders on May 7, 2026, where investors representing 54.22% of outstanding common shares were present by proxy and re-elected nine directors to the board. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight.

Investors approved an authorization for the board to implement one or more reverse stock splits within two years, at a ratio between 1-for-2 and 1-for-250, giving management flexibility to manage the share price and listing compliance. Shareholders further approved the 2026 Stock Incentive Plan, signaling support for equity-based compensation tools that may help Tonix attract and retain key talent in a competitive biotech market and align employee incentives with long-term shareholder value.

The most recent analyst rating on (TNXP) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.

Spark’s Take on TNXP Stock

According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.

The score is held down primarily by weak financial fundamentals—large ongoing operating losses and sustained cash burn—despite improving revenue and gross margin and a low-debt balance sheet. Technical signals are neutral-to-soft with negative MACD and price below longer-term averages, while valuation is difficult to support given losses and no dividend. Offsetting these factors, corporate updates are constructive, highlighted by expanded TONMYA reimbursement coverage and continued pipeline progress.

To see Spark’s full report on TNXP stock, click here.

More about Tonix Pharma

Tonix Pharmaceuticals Holding Corp. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for central nervous system conditions and other unmet medical needs. The company’s strategy relies on advancing its pipeline and maintaining access to capital markets, supported by governance structures that align management and shareholder interests.

Average Trading Volume: 404,493

Technical Sentiment Signal: Sell

Current Market Cap: $208.7M

For an in-depth examination of TNXP stock, go to TipRanks’ Overview page.